stockrowADMA Biologics Inc
ADMA Healthcare Biotechnology
ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024.
- Revenue
- +5.12%
- EPS
- +46.7%
- Free cash flow
- +1,709.5%
- Total debt
- +140.5%
Quarter to September 2026, against a year earlier
Follow ADMA
Alert me
ADMA Biologics Inc (ADMA) Shares outstanding
ADMA Biologics Inc's shares outstanding at the end of fiscal 2025 was $244.9M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $225.8M. Over the past ten years it has ranged from $10.4M (fiscal 2015) to $244.9M (fiscal 2025) — the current reading is the highest in ten years. ADMA Biologics Inc ranks 36th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $244.9M | 0.64% |
| FY2024 | $243.3M | 8.65% |
| FY2023 | $224.0M | 13.19% |
| FY2022 | $197.9M | 41.77% |
| FY2021 | $139.6M | 62.03% |
| FY2020 | $86.1M | 58.51% |
| FY2019 | $54.3M | 20.27% |
| FY2018 | $45.2M | 97.37% |
| FY2017 | $22.9M | 88.40% |
| FY2016 | $12.2M | 16.72% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $225.8M | (1.96%) |
| Jun 2026 | $230.3M | (4.01%) |
| Mar 2026 | $240.0M | (2.02%) |
| Dec 2025 | $244.9M | 0.10% |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ADMA ADMA Biologics Inc | $225.8M |
| BHVN Biohaven Ltd. compare | $151.0M |
| AUPH Aurinia Pharmaceuticals Inc compare | $135.2M |
| IMNM Immunome, Inc. compare | $113.3M |
| CLDX Celldex Therapeutics, Inc. compare | $77.8M |
| VERA Vera Therapeutics, Inc. compare | $71.8M |
| PHVS Pharvaris N.V. compare | $68.1M |
| VCEL Vericel Corporation compare | $53.0M |
| PVLA Palvella Therapeutics, Inc. compare | $14.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on ADMA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement